These agreements are very long and complex. They have been amended a few times, because situations have evolved. We've had to adjust to the situations. I have not—full disclosure—reviewed the agreements in detail before coming here.
Again, you talked about indemnity, you talked about pricing and you talked about trade secrets. There could be some IP. IP is not just a full-on five-pager of a recipe for a vaccine. IP could be woven into some areas. There could be some IP in the agreement in areas. Anything that has to do with the supply chain is really sensitive and confidential as well.